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1 4 .  A B S T R A C T
A major goal of this CTDA proposal is to optimize NF1 subject recruitment into 3 clinical trials related to MPNSTs. This CTDA project has 
been successful in being directly responsible for the implementation of 1 of the 3 clinical trials. Our initial efforts led to the submission of a 
clinical trial for neoadjuvant chemotherapy in MPNST (DAMD-NF043129; PI-David Viskochil). This proposal was not funded, however it was 
revised by Brigitte Widemann, M.D. as principal investigator with a dedicated focus on treatment of MPNSTs within an oncology Consortium 
(Sarcoma Alliance for Research through Collaboration, known as SARC). This revision entitled: PHASE II TRIAL OF NEOADj Uv ANT 
CHEMOTHERAPY IN SPORADIC AND NF1-ASSOCIATED HIGH GRADE UNRESECTABLE MPNSTs (Proposal #NF050022; PI-Brigitte 
Widemann) was approved for funding through the 2005 DOD NF Program. A meeting between investigators in this MPNST CTDA project 
and members of an MPNST Committee of a newly formed NF1 Consortium (DoD contract #W81XWH-05-1-615; PI-Jeannette Lee) and a 
representative of SARC was held in April, 2006, which allowed for the transition of aims from another CTDA-derived clinical trial 
(Identification of Risk Factors for MPNST in NF1) to potential implementation of its goals into an MPNST trial conducted through the NF1 
Consortium. Finally, website development from the CTDA study is being implemented for the recruitment and the enrollment of NF1 patients 
with spine abnormalities into a multi-center natural history study (R01 NS050509-01A1; PI-D. Viskochil).
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INTRODUCTION
A major goal of this CTDA proposal is to optimize subject recruitment in each of the clinical 
trials. Using the prevalence estimate for NF1 as 1 in 3,500 individuals in the population at large 
coupled with the cross-sectional estimate of 5% affected by MPNST, we acknowledge that few 
centers will have more than 2 patients with MPNST and NF1 in any given year. We anticipate 1 in 
1,750,000 people will develop MPNST and NF1 on an annual basis, thus the populations of the US, 
Canada, and Europe will provide a maximum of 50 cases per year. Our goal is to recruit at least 2/3 
of this cohort for enrollment in at least 1 of the 3 clinical trials. By developing a well-publicized 
network of NF1 Clinic Centers and Sarcoma Centers, we plan to offer enrollment to every 
individual in North America and Europe who has MPNST and NF1 into the case-control trial to 
identify risk factors for MPNST (clinical trial project 1). Based on inclusion and exclusion criteria, 
some individuals will be eligible for the clinical trial of neoadjuvant chemotherapy, and this will be 
offered to them as a treatment option (clinical trial project 3). Subjects with symptomatic 
peripheral nerve sheath tumors will be offered enrollment in the PET scanning surveillance study, 
but this is limited to specific centers where PET scanning is available (clinical trial project 2). 
Nevertheless, those who have MPNST detected as part of clinical trial project 2 will be offered 
enrollment in projects 1 and 3. Finally, a portion of every MPNST that is biopsied or resected will 
be sent to the tumor repository at Washington University for routine analysis and storage. This core 
will be administered by Mark Watson, and clinicopathologic studies will be performed under the 
guidance of Arie Perry. Tissue samples that are processed in a standardized way may provide the 
most significant outcome of this multi-center proposal. Distribution of this material to other 
laboratories that are performing research related to NF1 and/or MPNSTs may provide further 
insight to their molecular pathology.
The Advisory Board and Data Analysis Committee will develop the protocols and consent 
forms for each clinical trial, and the Administrative Core will provide interface for each local 
recruitment institution via a WEB site. A goal of this proposal is to identify and recruit a set of 
institutions that are capable and willing to identify and enroll subjects for each of the 
respective clinical trials. This will entail an invitation to participate after protocols have been 
established through the respective committees, approved by the Advisory Board, and maintained on 
an interactive WEB site. This WEB site will be instrumental in optimizing patient recruitment and 
accrual, handling of image files between institutions, real-time data transfer, and collection and 
tracking of specimens.
KEY ACCOMPLISHMENTS
• MPNST Consortium Meeting, New York City, June, 2004
• Submission of Clinical Trial to the DoD NF Program, June, 2004 (not funded)
• Development of website through the Informatics Core of the General Clinic Research Center 
at the University of Utah for recruitment, enrollment, electronic protocol storage, standard 
operating procedures, database, and tracking.
• Submission of Clinical Trial to the DoD NF Program, February, 2005 (PI -  B. Widemann, 
funded). Anticipated enrollment in Fall, 2006
• Funding of an NF1 Consortium Site at the University of Utah, October, 2005
• MPNST Consortium Meeting, Atlanta, April, 2006
• Submission of proposal from MPNST Committee of the NF1 Consortium to the Governing 
Body for inclusion in a DoD proposal for funding a clinical trial(s) in August, 2006.
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BODY
Task I: Implement efficient electronic communications between all participants in the study.
Month 1 -  develop server access, passwords, and orientation (oversight -  Bernie LaSalle,
University of Utah) for primary investigators of each project. Develop a predetermined
schedule for monthly teleconferences between the primary investigators.
Months 2-6 -  all relevant documents imported into WEB site at University of Utah
Months 6-9 -  test reliability, data safety, confidentiality, access to dummy data on WEB site
We carried out monthly then biweekly teleconferences between in March 2004 and May
2004. Protocol documents were imported to a website and a database was developed to include 
entry of subjects from each of the 3 proposed projects. Bernie LaSalle supervised a team of 3 to 
develop a website for NF1 Centers and Sarcoma Centers to link with respect to MPNSTs. Mr. 
LaSalle presented this website to the primary investigators in a face-to-face meeting in New York 
City in early June of 2004. He was able to demonstrate access to documents, and outlined a tiered 
plan for different levels of data access. Sites that contributed subjects had full access to all 
information entered, whereas each site only had access to cumulative de-identified data from other 
centers. A system was established that enabled coordinators and center investigators to have 
restricted access to data. Project principal investigators and statisticians had access at all levels of 
the database.
This WEB site was not tested for reliability, data safety, or access to dummy data prior to 
the submission of a proposal for neoadjuvant therapy of MPNSTs. The primary focus of our WEB 
site was to recruit subjects for all three proposals outlined in the introduction of this report. Since 
our efforts were redirected specifically to a well-defined clinical trial that required treatment of 
MPNST, the eligibility for enrollment narrowed considerably and could be handled by the 
respective sarcoma centers. The focus on clinical trial project 3 de-emphasized the requirement for 
an extensive recruitment plan, which led to a decision to utilize a network of sarcoma centers with 
an organized administrative core for conduction of oncology trials. With the submission of the 
clinical trial our database managers simply refined the WEB site for storage, and did not activate.
Our collaboration with Bernie LaSalle and his informatics team in the Clinical Genetics 
Research Program of the General Clinic Research Center for the University of Utah was included in
2 grant proposals that have been successful. The first is a Department of Defense Neurofibromatosis 
Program award (DAMD-NF050159) entitled The University of Utah Clinical Genetics Research 
Program as an NF1 Consortium Site (PI -  David Viskochil; activated 10/15/05). Our informatics 
team will interact with the Operations Center of the NF1 Consortium to provide data and potentially 
serve as unpaid consultants in the development of databases and WEB-based data management. The 
second grant is an NIH proposal (R01 NS050509-01A1) entitled Spinal Abnormalities in 
Neurofibromatosis Type 1. It is a multi-center, 5-year project to assess the natural history of spine 
problems in children with NF1 (PI -  David Viskochil). Even though it is not a clinical trial, the 
demonstration of our collaboration with the informatics core of the University of Utah GCRC and 
its familiarity with NF1 translational research made this multi-center study feasible.
Dr. Widemann has also adopted a few of the protocol sheets that were part of our initial 
submission for her most recent proposal that has been funded through the DoD NF Program.
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Task II: Complete proposals for 3 clinical trial projects.
Months 1-2 -  each primary investigator finalizes their respective project goals and methods
Clinical Trial Project 1 (Jan Friedman): Identify a set of clinical, genetic and 
environmental risk factors that identify individuals with NF1 who are at highest risk 
to develop MPNSTs.
18Clinical Trial Project 2 (Rosalie Ferner): Determine the value of FDG positron 
emission tomography in descriminating between malignant and benign symptomatic 
peripheral nerve sheath tumors.
Clinical Trial Project 3 (Brigitte Widemann): Evaluate the effectiveness of neo­
adjuvant therapy in MPNST treatment.
Tissue Core (Arie Perry): Develop a centralized, accessible tissue repository for 
PNSTs, serum, genomic DNA, RNA, cDNA, with accessible database.
Tasks: Each primary investigator will finalize their respective projects in the form of 
specific aims of a multi-center grant proposal. This includes: 1) specific aims with 
hypotheses and subaims, 2) background and significance, 3) preliminary work, 4) methods 
with rationale, statistical approaches, and problems and limitations, and 5) budgetary 
considerations.
Week 6 -  Phase I meeting of the NF1-MPNST Advisory Board consisting of primary 
investigators and colleagues to formally present the initial drafts of the respective projects, 
to outline tasks for documents and procedure manuals, to define elements of a web-based 
database system for mutual use by personnel from each of the 5 primary sites, and nominate 
members of the Data Analysis Committee, the Tissue Core Advisory Committee, and the 
Authorship Committee.
Months 3-6 -  Review and modify each clinical trial project.
Documents will be entered in the web site for review by all primary investigators and 
colleagues selected by each primary investigator. Each project will be finalized and 
integrated into a single project.
Month 6 -  Phase II Meeting between primary investigators to fine-tune the budget and begin 
preparations for grant submission to the DOD NFRP.
Months 6-9 -  Prepare final grant proposal.
Participating centers will be formally enrolled with subcontracts between respective 
institutions. Overall budget will be composed.
The primary investigators for each project were also involved in an NIH multicenter R01 
grant submission to the NINDS for the 3 specific projects outlined above. The critiques for this 
proposal became available approximately 1 month after activation of this DoD Clinical Trial
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Development Award. After further discussions with the DoD on the definition of a clinical trial, the 
5 primary investigators decided to focus only on the project spearheaded by Dr. Brigitte Widemann 
(Evaluate the Effectiveness of Neoadjuvant Chemotherapy in MPNST Treatment). Our efforts 
culminated in the submission of a clinical trial proposal in response to the Broad Program 
Announcement from the NF Research Program (deadline end of June, 2004). The proposal was 
entitled; Phase II Trial of Neoadjuvant Chemotherapy in High-Grade, Unresectable Malignant 
Peripheral Nerve Sheath Tumors (DAMD-NF043129; PI -  David Viskochil). Due to the timing of 
the award and need for linking with Sarcoma centers, we shifted our efforts away from the 
University of Utah Data Management Facility to the recruitment of a group of sarcoma centers that 
established themselves as a multicenter consortium of academic oncology centers (SARC -  
Sarcoma Alliance for Research through Collaboration) that has extensive experience in the 
treatment of soft tissue malignancies (sarcomas). This collaboration arose as a direct result of the 
MPNST Consortium Meeting held in Aspen, Colorado in May of 2002, and was extended when 
David Viskochil and David Gutmann presented studies on MPNST in NF1 to the Connective Tissue 
Oncology Society (CTOS) annual meeting held in October, 2002. Almost all member of SARC 
attend the annual CTOS meeting, and discussions at the meeting led to the recognition by Lee 
Helman, M.D. and Brigitte Widemann, M.D. as primary investigators to develop a neoadjuvant 
chemotherapy trial to assess the effectiveness of chemotherapy in MPSNT. These collaborations 
united NF1 investigators working on NF1-related MPSNTs with the SARC organization.
This proposal (DAMD-NF043129) was not funded. Communications between the primary 
investigators in reviewing the critique summary statement led to a face-to-face meeting between Jan 
Friedman, David Viskochil and Brigitte Widemann at the Pediatric Branch of NCI in Bethesda 
Maryland in January of 2005. Deliberations from this meeting led to the decision to revise the 
original proposal and submit with a dedicated focus on treatment of MPNST using the SARC 
Consortium for the bulk of the study. Brigitte Widemann was appointed the Principal Investigator, 
and she submitted a clinical trial award proposal to the DOD NF Research Program in February,
2005. This proposal is entitled: PHASE II TRIAL OF NEOADJUVANT CHEMOTHERAPY IN 
SPORADIC AND NEUROFIBROMATOSIS TYPE 1 ASSOCIATED HIGH GRADE 
UNRESECTABLE MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (Proposal 
#NF050022), and it was funded. The study is presently under human subjects protocol review and 
budget negotiations. This was a successful outcome that resulted from the collaborations 
directly established under the Clinical Trials Development Award.
After full discussion, we have decided to proceed with submission of clinical trial 1 as a 
separate study. The goal of that trial was to identify a set of clinical, genetic and environmental risk 
factors that identify individuals with NF1 who are at highest risk to develop MPNSTs. Specific 
aims have been developed, and a draft of the objectives as developed by the co-investigators of this 
CTDA project is provided below:
Individuals with neurofibromatosis type 1 (NF1) are at a relatively high risk to develop a deadly 
sarcoma called malignant peripheral nerve sheath tumor (MPNST) that has a 5-year survival of 
about 25%. Earlier detection and appropriate treatment predicts less morbidity and less 
mortality. Presently, it is difficult to diagnose MPNST at an early stage in disease. The 
identification of a cohort of individuals with NF1 who may be at high risk for MPNST would 
enable health care practitioners to establish rigorous screening protocols for early detection of 
MPSNT in NF1. Our overall objective as outlined in this proposal is to identify a set of 
clinical, genetic, molecular and environmental factors that identify those individuals with NF1 
who are at highest risk to develop MPNSTs. We will use a cross-sectional case-control protocol
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to determine differences between individuals with NF1 who have MPNST versus those without 
MPNST.
Specific aim 1: To determine if “tumor burden” is higher in those individuals with NF1 who 
develop MPNST, and, if so, estimate a relative risk to develop MPSNT based on “tumor load”.
Specific aim 2: To identify historical factors that correlate with an altered relative risk to 
develop MPNST in NF1.
Specific aim 3: To identify molecular factors that correlate with an altered relative risk to 
develop MPNST in NF1.
As a case-control trial to identify those with NF1 who are at highest risk to develop MPNST, the 
defined objective and specific aims outlined herein will serve as the basis of a future proposal. 
Recognition that these aims could evolve from established MPNST clinical trials, including those 
through the NF1 consortium, led to the organization of a meeting between investigators involved in 
this CTDA and members of the MPNST committee of the NF1 Consortium (DoD contract 
#W81XWH-05-1—615; PI -  Jeannette Lee). The details of this meeting are highlighted in section 
for Task IV. The Univesity of Utah is a member of the Consortium (DAMD NF050159).
With full deliberation, the investigators involved in the CTDA elected to not pursue clinical 
trial 2. Dr. Ferner will continue to refine the techniques and application of PET (positron emission 
tomography) to peripheral nerve sheath tumors in the NF1 population. She will seek independent 
funding through the health services research system in the United Kingdom.
Task III: Develop a WEB site for data management
Months 1-2 -  Establish a core working group to modify existing database software. Primary 
investigators and their colleagues from each institution who will be handling data and 
statistical interpretation will be identified and serve on the WEB Site Development 
Subcommittee (WSDS). A subcommittee selected from the Data Analysis Committee with one 
database manager from the NNFF International Database at the University of British 
Columbia and one database manager from the General Clinical Research Center at the 
University of Utah will establish communication lines, distribute database templates, and 
establish draft guidelines for access and data manipulation.
Week 10 -  Phase II meeting of the Data Analysis Committee to review the projects outlined 
by the Advisory Board, especially the statistical approaches to each respective clinical trial. 
This meeting will also review the outlines for documents and procedure manuals and assign 
tasks to develop these items to a web-based database. Members will determine design 
elements to be included in the NF1-MPNST WEB site.
Months 4-6 -  Implement WEB site with each primary institution site.
Months 6-9 -  Complete troubleshooting and document the data access capabilities which 
will be included in the grant submission.
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This task was not accomplished because of the shift in focus to use the SARC consortium to 
oversee all aspects of the trial including patient recruitment, data management, safety monitoring, 
and statistical analysis. There was no need to fully implement the WEB site developed at the 
University of Utah if the SARC consortium was going to collaborate with Dr. Widemann in all 
aspects of the clinical trial.
The Informatics Core at the University of Utah prepared to become the administrative core 
of the secondary aims related to MPNST biology and imaging that was part of the phase II 
neoadjuvant trial, however with Dr. Widemann taking over as principal investigator in the 
resubmission on offsite administrative core was no longer needed for this trial. The focus on this 
project at the exclusion of the other 2 projects also minimized the need for an administrative core to 
optimize recruitment and data collection. Nevertheless, the informatics core developed a website 
that may prove useful in deliberations within the newly formed NF1 Consortium (DoD Program 
Announcement for May 5, 2005 submission).
As a result of the CTDA, a website has been developed through the administrative core at 
the University of Utah. As designed, access to the website will include both public and restricted 
access. The public access provides information for both physicians and the general public regarding 
definitions, descriptions of ongoing studies, links to participating centers and links to the NNFF 
(now CTF -  Childrens Tumor Foundation) and NF Inc. support group foundations. It focuses on 
those aspects related to MPNST. Restricted access to study data is securely provided through the 
use of Secure Socket Layer (SSL) technology and assigned username/password codes. The data 
under the SSL connection includes real time database reports regarding individual study 
participants. Each center is restricted to its own study population data. Summary enrollment data 
across all centers is also available to investigators. The restricted area contains a central document 
repository and up to date protocols for sample and image processing procedures. Access to the 
website is https://crcjs.med.utah.edu/mpnst_v2. This CTDA also funded a meeting in New York 
City where the website was demonstrated to participants and feedback was provided. This meeting 
provided Dr. Widemann with NFl-related MPNST information to present a version of her phase II 
neoadjuvant therapy trial at the Sarcoma Alliance for Research through Collaboration biannual 
meeting in June of 2004 in New Orleans. The SARC supported the trial concept, and the need to 
perform a clinical trial for high-grade, unresectable MPSNTs. SARC members confirmed their 
interest in participating in the planned trial should it be funded, and they stated that depending on 
the institution one could expect l-to-4 patients at each site per year who may be eligible for the 
planned trial. It gave great impetus to proceed with this trial and strengthen the collaboration with 
SARC and CTOS. Given the success of this transition of administrative support through SARC, the 
MPNST WEB site at the University of Utah did not go live. However, it is presently being adapted 
for a multicenter trial (funded by the NINDS as R01 NS050509-01A1) for the collection of clinical 
data from 4 centers to determine the natural history of spine abnormalities in a cohort of 120 
individuals with NF1. As an application of WEB site development for the clinical trial for spine 
abnormalities in NF1, this represents a successful outcome of the CTDA even though it is not 
directly related to the MPNST trials.
A flowchart was developed for the Clinical Trial Award submission (NF 043129) for 
enrollment and data and specimen collection, and it is depicted on the next page. It shows the efforts 
from each of the 5 centers (NCI in Bethesda, UBC in Canada, Guys Hospital in London, U of Utah 
(administrative core) and Washington University (tumor bank)).
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In addition, a summary document showing what was available on the University of Utah 
Website is provided below. An interactive set up within the columns and rows was developed for 
querying the database. An electronic set of protocols is also embedded within the website in order 
for coordinators at each site to readily access protocols and fill in data collection fields within web
1 0
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pages at the respective home sites. This is being modified to collect similar data for the Spinal 
Abnormalities Clinical Trial (PI -  David Viskochil, University of Utah). Mr. LaSalle and his 
informatics team of the General Clinic Research Center at the University of Utah are adopting the 
WEB-accessible database to emphasize issues related to bone in NF1. It is anticipated to go live by 
the end of 2006 in order to enroll subjects from the University of British Columbia, the University 
of Manchester, the University of Cincinnati, and the University of Utah.
The status o f data collection from the secondary objectives will be displayed through limited access website, and a 
prototype example is shown below.
THIS IS AN EXAMPLE ONLY. DOES NOT REFLECT ACTUAL ENROLLMENT
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Task IV: Recruit Sarcoma Centers and NF Centers for participation in each project.
Month 3 -  Identify potential participating centers for each of the 3 projects.
Months 4-8 -  Establish agreements with participating centers and document these
agreements in the form of support letters.
Month 9 -  Assimilate all support agreements in the grant submission.
This was a partially successful outcome. By shifting the focus of this clinical trial 
development award to chemotherapeutic intervention in MPNSTs rather than natural history trials 
attempting to identify predisposing factors leading to MPNST in the NF1 population, we de­
emphasized the development of NF1 centers and established an MPNST trial within an existing 
Sarcoma Consortium. The SARC centers were identified, and are now aware of the important 
association of MPSNTs and NF1.
There are a number Sarcoma Centers affiliated with academic institutions scattered 
throughout North America and Europe. Oncologists who specialize in sarcoma care have also 
organized themselves into a vibrant working group called the Connective Tissue Oncology Society 
(CTOS). In 2001, a number of members with common interest in sarcoma trials formed the North 
American Sarcoma Study Group of the CTOS to collaborate on clinical trial efforts. This loose-knit 
consortium opened its first trial in November, 2001 and a second one in January of 2003. By 
November of 2003, a formal structure was established with the application and incorporation of 
SARC (Sarcoma Alliance for Research through Collaboration) as a not-for-profit organization. 
SARC acts as an advocate for sarcoma medical research. Its primary role is to advocate for the 
conduct of clinical trials relating to treatments for sarcoma. SARC facilitates dialogue and 
collaboration among sarcoma researchers and clinicians, assists in the development and 
dissemination of protocols for clinical trials and information relating to sarcoma research and the 
results of clinical trials, administers research grants and funding for clinical trials, and acts as a 
primary resource for those treating sarcoma. Members of SARC include sarcoma experts from the 
following centers listed in APPENDIX 1. Membership requirements include multidisciplinary 
membership to the Connective Tissue Oncology Society and a commitment to sarcoma research.
As one of the rare sarcomas, MPNST is not a “high-profile” tumor. Therefore, we have 
elected to work with the SARC as the operations center to implement this phase II clinical trial. 
Unlike pediatric cancer trials developed through the Childrens Oncology Group, well-established 
clinical trials using protocols to treat MPNSTs in a consistent manner throughout the oncology 
community have not been widely instituted. In reviewing the oncology literature, there are 
approximately 10 clinical trials available for MPNSTs (clinicaltrials.gov web page), and 44 trials 
for unspecified soft tissue sarcomas. The support and involvement of SARC provides an 
infrastructure to maximize enrollment of these rare patients.
The DoD award to Dr. Widemann (NF050022) will ensure the establishment of participating 
centers that will also likely participate in future studies that include natural history studies of 
MPSNTs and NF1. David Viskochil has attended the last 3 meetings of the connective tissue 
oncology society meeting and he has presented posters at each. This annual meeting includes all the 
SARC consortium centers, and Dr. Viskochil will attend a SARC biannual meeting as a satellite 
meeting of the CTOS meeting in Boca Raton, Florida on November 17, 2005. The next meeting is 
scheduled November 2-4, 2006, and Dr. Viskochil will present a poster on loss of heterozygosity of 
the NF1 gene in tibial pseudarthrosis tissue derived from individuals with NF1. There are no other 
geneticists at this meeting, and his presence will enable the sarcoma center personnel to continue to
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recognize the association of NF1 with MPNST. An associate of Dr. Widemann will present the 
protocol of the DAMD proposal to SARC representatives. There are only 6 sarcoma treatment trials 
that are presently administered by the SARC consortium, and this protocol would be one of the 
trials. Dr. Widemann has recruited the following centers for her Phase II study:
Selected neurofibromatosis type 1 and pediatric sarcoma referral centers:
Steward Goldman, MD, Children’s Memorial Hospital, Chicago, IL 
Regina Jakacki, MD, Children’s Hospital of Pittsburgh, Pittsburgh, PA 
Nita Seibel, MD, Children’s National Medical Center, Washington, DC 
Jean Belasco, MD, Children’s Hospital of Philadelphia, Philadelphia, PA 
Robert Arceci, MD, Johns Hopkins Oncology Center, Baltimore, MD 
Alyssa Reddy, MD, University of Alabama at Birmingham, AL 
John Perentesis, MD, Cincinnati Children’s Hospital, Cincinnati, OH 
Allison King, MD, St. Louis Children’s Hospital, St. Louis, MO 
Christopher Moertel, MD, Children’s Hospitals and Clinics of MN, St.Paul, MN
In addition to the identification of participating sarcoma centers for Dr. Widemann’s clinical 
trial, investigators of the CTDA met with MPNST committee members of the newly established 
NF1 consortium (DoD contract #W81XWH-05-1-615; PI -  Jeannette Lee). The NF1 Consortium 
is comprised of 9 sites in the United States and an Operations Center. Its objectives are 1) to 
accelerate the clinical translation of basic NF1 research and ultimately decrease the overall impact 
of the disease, and 2) Conceive, develop, and conduct collaborative pilot, phase I and II clinical 
evaluations of promising therapeutic agents or approaches for the management or treatment of NF1. 
The 9 sites are academic centers from Birmingham, Boston, Washington DC, Cincinnati, Bethesda, 
Chicago, St. Louis, and Utah. The meeting between the MPNST Consortium of the CTDA and the 
MPSNT committee of the NF1 Consortium was organized by Dr. Viskochil to transition the goals 
of 1 of the CTDA-developed studies (identify risk factors for the development of MPNST in NF1) 
to implementation by incorporation into clinical trials for MPNST developed through the NF1 
Consortium. The meeting was held on April 6, 2006 in conjunction with the NF1 Consortium 
Meeting that was held on April 7, 2006 in Atlanta. In addition to members of the MPNST 
Committee of the NF1 Consortium and members of the MPNST Consortium from the CTDA, Dr. 
Larry Baker from SARC joined us to review progress by CTDA investigators and inform the 
attendees about the infrastructure of SARC. Attendees to this meeting are bolded in the list on the 
next page
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MPNST Committee of the NF1 Consortium
Chairs:
John Perentesis, University of Cincinnati (john.perentesis@cchmc.org)
Karen Albritton, Harvard University (karen albritton@dfci.harvard.edu)
Pablo Arnoletti, University of Alabama, Birmingham (Pablo.Arnoletti@ccc.uab.edu)*
- Belasco, Childrens Hospital of Philadelphia (BELASCO@email.chop.edu)*
David Gutmann, Washington University (gutmannd@neuro.wustl.edu)*
Martin Nicholas, University of Chicago (mnichola@neurology.bsd.uchicago.edu)*
Roger Packer, Childrens National Medical Center, Washington, DC (rpacker@cnmc.org)* 
Terrence Peabody, University of Chicago (tpeabody@surgery.bsd.uchicago.edu)*
Arie Perry, Washington University (apry@pathology.wustl.edu)*
John Pressey, University of Alabama, Birmingham (JPressey@peds.uab.edu)*
James Tonsgard, University of Chicago (tonsgard@midway.uchicago.edu)*
David Viskochil, University of Utah (dave.viskochil@hsc.utah.edu)
Brian Weiss, University of Cincinnati (brian.weiss@cchmc.org)
Brigitte Widemann, NCI, Pediatric Branch, Bethesda (widemanb@mail.nih.gov)
Jeannette Lee, University of Alabama, Birmingham (jylee@uab.edu)
Karen Cole, University of Alabama, Birmingham (Karen.Cole@ccc.uab.edu)*
MPNST Consortium from the Clinical Trials Development Award (DoD)
Rosalie Ferner, Guys and St. Thomas Trust, London, UK 
Jan Friedman, University of British Columbia, Vancouver, CA 
Arie Perry, Washington University*
David Viskochil, Univeristy of Utah 
Brigitte Widemann, NCI, Pediatric Branch
Ad hoc Invitees
Laurence Baker, University of Michigan (SARC) 
Karen Cichowski, Harvard University 
Shyra Miller, University of Cincinnati
Dr. Jeannette Lee is the PI for the NF1 Consortium Operations Center. She oversaw the submission 
of the Clinical Trials Proposal that was submitted in August, 2006 in response to a Program 
Announcement by the DoD NF Program. The chairs for the MPNST Committee of the NF1 
Consortium are Drs. John Perentesis and Karen Albritton. Drs. Karen Chichowski and Shyra Miller 
are ad hoc attendees who gave presentations to the group. The agenda for the meeting is provided 
below:
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AGENDA
0930 Introductions; past history of MPNST consortium - D Viskochil
1000 Summary of MPSNT protocol(s) for the NF1 Consortium - J Perentesis
1030 Epidemiology of MPNST in NF1 - J Friedman
1100 Diagnostic Imaging of MPNST and Plexiform neurofibromas - R Ferner
1130 Clinical Trial of Neoadjuvant Therapy in NF1 - B Widemann
1200 SARC - L Baker
1230 Lunch
1300 Ras-neurofibromin Signal Transduction Pathway - K Cichowski
1330 Gene Expression Patterns in Peripheral Nerve Sheath Tumors -  S Miller
1400 Immunohistochemical Patterns in PNSTs -  D Viskochil
1430 Break
1500 Open Discussion on Potential Protocols
Anticipated Meeting Outcomes
Identify potential biologic agents for future clinical trials
Specify primary and secondary endpoints for MPNST treatment protocols
Identify limitations of NF1 Consortium and Operations Center in MPNST Trials
List collaborative agencies that could facilitate NF1 MPNST Trials
Identify mechanisms to enroll MPNST and control subjects into longitudinal registries
At the conclusion of the meeting the attendees had addressed the above agenda items. A 
major outcome was the identification of 2 unique signaling pathway targets for MPNST treatment 
protocols, Erk in the mitogen activated protein kinase pathway and mTOR. The endpoints for 
treatment protocols were accepted as survival and tumor response by volume loss. Limitations of 
multicenter trials were described, and attendees acknowledged the value of consortia to enroll and 
complete data acquisition with due respect for safety monitoring. Presently, the 2 collaborative 
agencies that are prepared to facilitate NF1 MPNST trials were identified as the NF1 consortium 
and SARC. Mechanisms to enroll patients and controls for longitudinal registries were viewed as 
intimately tied to the roll-out of protocols for treatment of NF1-associated MPNSTs.
Over the course of the ensuing months Drs. Brian Weiss and Brigitte Widemann worked 
closely with the chairs to develop a clinical trial for MPNST that was included in the DoD proposal 
submitted by Dr. Lee for 4 clinical trials. The MPNST trial was embedded in section 8 of the 
proposal, and the primary hypothesis which evolved in part from the April meeting states: Targeted 
inhibition of signaling pathways upstream and downstream of the ras/NF1 pathway (e.g. Raf, P13K, 
RalGEF) will effectively and selectively inhibit the growth and progression of NF1-related MPNST. 
The primary specific aim to address this hypothesis is: To determine if combination multikinase 
inhibitors and chemotherapy will be effective in treating children with NF1 and relapsed MPNST. 
This protocol is tied to those individuals who have entered and not responded to Dr. Widemann’s 
protocol (PHASE II TRIAL OF NEOADJUVANT CHEMOTHERAPY IN SPORADIC AND 
NEUROFIBROMATOSIS TYPE 1 ASSOCIATED HIGH GRADE UNRESECTABLE MPNSTs), 
and demonstrates the value of linking the SARC infrastructure with the NF1 Consortium.
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CONCLUSION
This project has been successful in being directly responsible for the implementation of a clinical 
trial for MPNSTs in NF1 patients (project 3). It has not led to the successful implementation of 
clinical studies outlined in projects 1 and 2. We have elected to drop ongoing pursuit of funding for 
the studies outlined in project 2. This decision was predicated on discussions between radiologists 
familiar with PET scanning in sarcoma centers, which took place in the face-to-face meeting in 
New York City and teleconference calls as part of the planning for the neoadjuvant chemotherapy 
clinical trial. The PET protocols outlined by Dr. Ferner in project 2 may not be enthusiastically 
implemented in the United States. The studies outlined in project 1 to identify individuals with NF1 
at higher risk to develop MPNST have been refined and will be submitted for funding review in the 
future. A final face-to-face meeting of the MPNST Consortium of the CTDA was held with the 
MPNST Committee of a newly formed NF1 Consortium and a representative from the Sarcoma 
Alliance for Research through Collaboration (SARC) to transition deliberations and protocol design 
for this clinical trial to implementation with active trials.
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